Nektar Therapeutics (NKTR)
(Delayed Data from NSDQ)
$22.45 USD
-0.11 (-0.49%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $22.51 +0.06 (0.27%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Fundamental Charts
About Market Cap
As of the previous market close, Nektar Therapeutics has a market cap of $279.90M, which represents its share price of $22.56 multiplied by its outstanding shares number of 12.41M. As a small-cap company, NKTR's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
NKTR 22.45 -0.11(-0.49%)
Will NKTR be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for NKTR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NKTR
Rigel Pharmaceuticals (RIGL) Q2 Earnings and Revenues Surpass Estimates
Nektar Gears Up to Report Q2 Earnings: What's in the Cards?
NKTR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Journey Medical Corporation (DERM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
NKTR Stock Soars as Lead Drug Meets Goal in Atopic Dermatitis Study
Strength Seen in Nektar (NKTR): Can Its 12.1% Jump Turn into More Strength?
Other News for NKTR
Nektar to Announce Financial Results for the Second Quarter on Thursday, August 7, 2025, After ...
Nektar gets FDA fast track status for alopecia areata drug
Nektar (NKTR) Gains FDA Fast Track Status for Alopecia Areata Treatment
Nektar's rezpegaldesleukin granted Fast Track Designation in alopecia areata
Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of ...